Real-world data on nivolumab treatment of non-small cell lung cancer

Acta Oncologica

Volumn 56, Issue 3, 2017, Pages 438-440

  Brustugun, O T ^a,b   Sprauten, M ^a   Helland, A ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; MINERALOCORTICOID; NIVOLUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANAPHYLAXIS; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL EVALUATION; COLITIS; DIARRHEA; DISEASE COURSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; HEALTH PROGRAM; HISTOPATHOLOGY; HUMAN; HYPOPHYSIS DISEASE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PERSONAL EXPERIENCE; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RASH; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SIDE EFFECT; SQUAMOUS CELL LUNG CARCINOMA; TIME TO TREATMENT; TREATMENT INDICATION; WEIGHT GAIN; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; COHORT ANALYSIS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84997606182     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/0284186X.2016.1253865     Document Type: Article

References (8)

1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639.
2. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135.
3. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial. Lancet. 2016;387:1540–1550.
4. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR):a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837–1846.
5. Saturni S, Bellini F, Braido F, et al. Randomized controlled trials and real life studies. approaches and methodologies:a clinical point of view. Pulm Pharmacol Ther. 2014;27:129–138.
6. Böhm S, Montfort A, Pearce OM, et al. Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma. Clin Cancer Res. 2016;22:3025–3036.
7. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–2028.
8. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–1597.